Introduction: Severity and seriousness assessment of ADRs is a core pharmacovigilance topic for B. Pharm students. Understanding adverse drug reactions (ADRs), differentiating severity from seriousness, and applying assessment tools like Hartwig’s scale, CTCAE, and WHO‑UMC criteria are essential skills. Accurate ADR classification, causality judgment, preventability evaluation, and timely reporting to regulatory agencies improve patient safety and inform risk management. Key concepts include hospitalization, life‑threatening events, disability, death, and expectedness. This knowledge supports clinical decision making, signal detection, and quality drug therapy. Now let’s test your knowledge with 30 MCQs on this topic.
Q1. What is the primary difference between “severity” and “seriousness” in ADR assessment?
- Severity describes the intensity of an ADR; seriousness relates to regulatory outcomes like hospitalization or death.
- Severity and seriousness are synonyms and used interchangeably in pharmacovigilance.
- Seriousness describes the intensity; severity relates to legal consequences.
- Severity is only used for chronic ADRs; seriousness is only for acute ADRs.
Correct Answer: Severity describes the intensity of an ADR; seriousness relates to regulatory outcomes like hospitalization or death.
Q2. Which of the following is a standard criterion that defines a “serious” adverse event?
- Transient mild rash requiring no treatment
- Hospitalization or prolongation of existing hospitalization
- Minor nausea resolving in a few hours
- Temporary taste alteration
Correct Answer: Hospitalization or prolongation of existing hospitalization
Q3. Which scale is commonly used to grade the severity of adverse events in oncology clinical trials?
- Hartwig Severity Assessment Scale
- Schumock and Thornton Preventability Scale
- Common Terminology Criteria for Adverse Events (CTCAE)
- WHO-UMC Causality Scale
Correct Answer: Common Terminology Criteria for Adverse Events (CTCAE)
Q4. The Hartwig severity scale primarily assesses which aspect of an ADR?
- Regulatory seriousness for reporting
- Intensity and level of medical intervention required
- Causality between drug and event
- Cost of treating the ADR
Correct Answer: Intensity and level of medical intervention required
Q5. Which of the following is considered a “serious” outcome by ICH guidelines?
- Mild insomnia
- Congenital anomaly or birth defect
- Self-limited headache
- Minor injection site redness
Correct Answer: Congenital anomaly or birth defect
Q6. In ADR terminology, what does “expectedness” refer to?
- Whether the ADR is predictable based on the drug’s known safety profile
- Severity score assigned by the patient
- Whether the ADR is legally actionable
- Whether the ADR causes permanent disability
Correct Answer: Whether the ADR is predictable based on the drug’s known safety profile
Q7. Which tool assesses preventability of an ADR?
- WHO-UMC Causality Assessment
- Schumock and Thornton Preventability Criteria
- CTCAE grading
- MedDRA coding
Correct Answer: Schumock and Thornton Preventability Criteria
Q8. When an ADR causes permanent impairment or disability, how is it classified?
- Non-serious and minor
- Serious because it results in persistent disability
- Expected and not reportable
- Only severe if it required ICU care
Correct Answer: Serious because it results in persistent disability
Q9. Which organization developed the WHO‑UMC causality categories used globally?
- Food and Drug Administration (FDA)
- European Medicines Agency (EMA)
- World Health Organization–Uppsala Monitoring Centre (WHO‑UMC)
- International Council for Harmonisation (ICH)
Correct Answer: World Health Organization–Uppsala Monitoring Centre (WHO‑UMC)
Q10. Which MedDRA term level is most appropriate for coding a specific ADR in a safety database?
- System Organ Class (SOC)
- Preferred Term (PT)
- High Level Group Term (HLGT)
- Lower Level Term (LLT)
Correct Answer: Preferred Term (PT)
Q11. A drug causes severe anaphylaxis requiring adrenaline and ICU admission. How should seriousness and severity be recorded?
- Serious: yes; Severity: severe (high grade)
- Serious: no; Severity: mild
- Serious: yes; Severity: mild
- Serious: no; Severity: severe
Correct Answer: Serious: yes; Severity: severe (high grade)
Q12. Which of the following best describes “life‑threatening” in seriousness criteria?
- An event that could have resulted in death at the time of the event
- An event that is painful but not dangerous
- A chronic condition unrelated to the drug
- A minor laboratory abnormality without clinical consequences
Correct Answer: An event that could have resulted in death at the time of the event
Q13. Which assessment should be performed first when a suspected ADR is reported?
- Severity grading only
- Immediate causality, seriousness, and necessary medical actions
- Preventability assessment only
- Regulatory submission without evaluation
Correct Answer: Immediate causality, seriousness, and necessary medical actions
Q14. In clinical trials, an unexpected serious ADR must be reported as:
- An annual safety update only
- An expedited SUSAR (Suspected Unexpected Serious Adverse Reaction)
- A routine investigator note in the file
- Not reported if the investigator feels it is unrelated
Correct Answer: An expedited SUSAR (Suspected Unexpected Serious Adverse Reaction)
Q15. Which statement about severity scales is true?
- Severity scales measure regulatory impact only.
- Severity scales quantify clinical intensity and guide management decisions.
- Severity scales are universally identical across all therapeutic areas.
- Severity scales replace the need for causality assessment.
Correct Answer: Severity scales quantify clinical intensity and guide management decisions.
Q16. An ADR that requires discontinuation of the drug but no hospitalization is usually classified as:
- Non-serious and severe depending on intensity
- Always non-severe and non-serious
- Automatically life-threatening
- Not an ADR
Correct Answer: Non-serious and severe depending on intensity
Q17. Which factor does NOT directly determine the seriousness of an ADR?
- Whether it results in death
- Requirement for hospitalization
- Intensity of patient-reported discomfort if no other outcomes
- Causing congenital anomaly
Correct Answer: Intensity of patient-reported discomfort if no other outcomes
Q18. How does causality assessment differ from severity assessment?
- Causality determines blame to the manufacturer; severity measures attorney involvement.
- Causality evaluates the likelihood the drug caused the event; severity measures the event’s intensity.
- They are identical processes with different names.
- Severity assesses expectedness; causality assesses preventability.
Correct Answer: Causality evaluates the likelihood the drug caused the event; severity measures the event’s intensity.
Q19. Which of these is an example of an “important medical event” that may be classified as serious even without hospitalization?
- Mild transient cough
- Severe allergic reaction requiring urgent intervention but not hospitalization
- Brief dizziness lasting minutes and resolving
- Minor arthralgia responding to analgesics
Correct Answer: Severe allergic reaction requiring urgent intervention but not hospitalization
Q20. For regulatory reporting, which time frame is commonly required for initial expedited reporting of a fatal or life‑threatening SUSAR?
- Within 7 calendar days for fatal/life-threatening; follow-up within 8 days
- Within 90 days only
- Only at the end of the study
- No specific timeframe
Correct Answer: Within 7 calendar days for fatal/life-threatening; follow-up within 8 days
Q21. Which approach improves objectivity in severity assessment?
- Using validated scales like CTCAE or Hartwig rather than only subjective opinion
- Relying solely on patient-reported adjectives like “mild” or “severe”
- Using financial cost as the main metric
- Avoiding documentation to reduce bias
Correct Answer: Using validated scales like CTCAE or Hartwig rather than only subjective opinion
Q22. A mild lab abnormality without symptoms may be graded as severe if:
- It meets CTCAE criteria for grade 3 or higher
- The patient feels mild discomfort
- It is expected from the drug label
- It occurred on the first day of therapy
Correct Answer: It meets CTCAE criteria for grade 3 or higher
Q23. Which best practice should a pharmacist follow when coding an ADR in a safety database?
- Use the most specific MedDRA term available (LLT or PT) to reflect the event
- Always code events under general SOC without details
- Invent new terms to better describe novel reactions
- Omit coding if the event is non-serious
Correct Answer: Use the most specific MedDRA term available (LLT or PT) to reflect the event
Q24. Which is a limitation of severity assessment based on patient self-report?
- High objectivity and reproducibility
- Potential subjectivity and variability between patients
- It always correlates with seriousness
- It replaces laboratory and clinical evaluation
Correct Answer: Potential subjectivity and variability between patients
Q25. In the context of ADRs, “dechallenge” refers to:
- Re-exposure to the suspect drug to provoke the reaction
- Stopping the drug to see if the ADR resolves
- Reporting the ADR to regulatory authority
- Assigning a severity grade
Correct Answer: Stopping the drug to see if the ADR resolves
Q26. Rechallenge information is most useful for:
- Determining preventability only
- Strengthening causality assessment if ethically and clinically appropriate
- Automatically classifying the event as non-serious
- Deciding the cost of therapy
Correct Answer: Strengthening causality assessment if ethically and clinically appropriate
Q27. Which is true about reporting a serious unexpected ADR observed in practice?
- It should be reported to national pharmacovigilance centers promptly regardless of causality certainty
- It should be reported only if the manufacturer requests it
- It should never be reported if the patient recovers
- Reporting is optional for serious events
Correct Answer: It should be reported to national pharmacovigilance centers promptly regardless of causality certainty
Q28. Which parameter is most helpful to distinguish severity grades in CTCAE?
- Patient’s income level
- Impact on activities of daily living and need for medical intervention
- Brand name of the drug
- Time of administration
Correct Answer: Impact on activities of daily living and need for medical intervention
Q29. A transient, non‑life‑threatening lab abnormality that requires no intervention is typically:
- Serious and always reportable as SUSAR
- Non-serious and may be graded mild in severity
- Life‑threatening by default
- Preventable only if it causes hospitalization
Correct Answer: Non-serious and may be graded mild in severity
Q30. For a B. Pharm graduate working in pharmacovigilance, which skill is most important for assessing ADR severity and seriousness?
- Ability to perform complex surgeries
- Knowledge of clinical criteria, validated severity scales, regulatory definitions, and clear documentation
- Proficiency in unrelated laboratory assays
- Marketing and promotional skills only
Correct Answer: Knowledge of clinical criteria, validated severity scales, regulatory definitions, and clear documentation
